ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.

Quote:

Search for Ticker

Free Membership

Search:

ALXA: Alexza Pharmaceuticals Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

ALEXZA PHARMACEUTICALS INC (NASD)
ALXA	2.28	0.06	(2.70%)	Vol. 29,842	16:00 ET

Alexza Pharmaceuticals is an emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

General Information

ALEXA PHARMACT

- -, - - Phone: - Fax: - Web: - Email: None

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	03/09/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	2.22
52 Week High	3.53
52 Week Low	1.30
Beta	1.66
20 Day Moving Average	105,741.95
Target Price Consensus	6.4

% Price Change
4 Week	-5.00
12 Week	-15.56
YTD	-28.08

% Price Change Relative to S&P 500
4 Week	-6.03
12 Week	-20.39
YTD	-40.47

Share Information
Shares Outstanding (millions)	33.25
Market Capitalization (millions)	75.81
Short Ratio	3.18
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.23
Current Year EPS Consensus Estimate	-0.95
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	03/09/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.67
30 Days Ago	1.67
60 Days Ago	1.67
90 Days Ago	1.67

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	-337.78%
vs. Previous Quarter	-603.57%

Sales Growth
vs. Previous Year	-%
vs. Previous Quarter:	2,181.53%

Price Ratios
Price/Book	3.95
Price/Cash Flow	-
Price / Sales	-

ROE
09/30/09	-336.14
06/30/09	-116.32
03/31/09	-100.23

ROA
09/30/09	-144.61
06/30/09	-50.84
03/31/09	-46.62

Current Ratio
09/30/09	-
06/30/09	2.24
03/31/09	3.43

Quick Ratio
09/30/09	-
06/30/09	2.24
03/31/09	3.43

Operating Margin
09/30/09	-
06/30/09	-
03/31/09	-

Net Margin
09/30/09	-
06/30/09	-625.30
03/31/09	-655.80

Pre-Tax Margin
09/30/09	-
06/30/09	-625.30
03/31/09	-655.80

Book Value
09/30/09	-
06/30/09	0.58
03/31/09	1.03

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	-
06/30/09	0.00
03/31/09	0.05

Debt to Capital
09/30/09	-
06/30/09	5.80
03/31/09	4.96


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research